SOBI:STO price falls below 15-day moving average to 140.60 at 14:24 BST Apr 19 2021 Key statistics On Friday, Swedish Orphan Biovitrum AB (publ) (SOBI:STO) closed at 144.00, 6.35% above its 52-week low of 135.40, set on Mar 04, 2021.

Swedish Orphan Biovitrum AB (publ) (Sobi™) har publicerat års-och hållbarhetsredovisningen för 2020. Redovisningen sammanfattar vår affärsverksamhet och strategi, vårt finansiella resultat samt vårt hållbarhetsarbete.

At Sobi, we are transforming the lives of people affected by rare diseases. We are providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications. Results centre. Swedish Orphan Biovitrum. 144,00. SEK-0,35 SEK-0,24%.

| Sobi is a specialised international biopharmaceutical company transforming the lives of people with rare diseases. We are providing sustainable access to innovative therapies in the areas of haematology, immunology and specialty indications Sobi, en tant qu’acteur majeur dans le domaine des maladies rares collabore en toute transparence avec des professionnels de santé et des associations. En savoir plus. Sobi. Spécialiste en protéines recombinantes thérapeutiques.

Oelkers had previously been CEO of BSN medical [ de].

OM:SOBI CEO Compensation July 14th 2020 A Look at Swedish Orphan Biovitrum AB (publ)'s Growth Numbers . Over the past three years, Swedish Orphan Biovitrum AB (publ) has seen its earnings per share (EPS) grow by 67% per year. Its revenue is up 49% over the last year.

Läkemedel & Handel. Swedish Orphan Biovitrum, även kända under namnet Sobi, är ett internationellt läkemedelsbolag. Störst inriktning återfinns inom tillhandahållandet av innovativa behandlingar och service för patienter med sällsynta sjukdomar.

Sobi marknadsför även särskilda specialist- och särläkemedel. Huvudkontoret ligger i Stockholm. Kalender. 2021-10-28, Kvartalsrapport 2021-Q3.

”Sobi har Om någon vet är det Lars Sandström, CFO på SOBI - Swedish Orphan Biovitrum.

159.3. -0.20. -0.13%.
Matte b

At Sobi, we are transforming the lives of people affected by rare diseases. | Sobi is a specialised international STOCKHOLM, April 26, 2021 /PRNewswire/ -- On 4 May, at 08:00 CEST, Swedish Orphan Biovitrum AB (publ) (Sobi™) will publish its report for the first quarter 2021. Investors, financial analysts and media are invited to participate in a telephone conference, which will include a presentation of the results, on the same day at 13:00 CEST .

Swedish Orphan Biovitrum Ltd. mail.uk@sobi.com +44-1223 891 854. Suite 2, Riverside 3, Granta Park, Great Abington Cambridgeshire, CB21 6AD. International contacts. Swedish Orphan Biovitrum (Sobi) är ett läkemedelsföretag med två fokusområden: hemofili och sällsynta sjukdomar.
Bbic utbildning distans

gymnasium.se yrkesguiden
medelåldern i sverige 2021
tv-profil döms för misshandel på restaurang
teaterhogskolan
hastighetsskyltar med tid
bb kristianstad nyfödda

2019-9-30

Revenue News stories and articles referencing Swedish Orphan Biovitrum (SOBI) on European Pharmaceutical Review. Get the latest Swedish Orphan Biovitrum AB (publ) (SOBI) real-time quote, historical performance, charts, and other financial information to help you make more Dova Pharmaceuticals is set to be acquired by Swedish Orphan Biovitrum AB ( Sobi) for up to $915m, dependent on the regulatory approval It was cleared by Stockholm, Sweden, 12 November 2019. Sobi successfully completes acquisition of Dova Pharmaceuticals. Swedish Orphan Biovitrum AB (publ) (Sobi Sobi is an international biopharmaceutical company focused on providing access to innovative treatments for rare diseases.

Swedish Orphan Biovitrum har brutit den fallande t This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title. It can be a long snippet, a short snippet, whatever you prefer the size of card and description to be.This is the body text of the blog post to give visitors an idea of what the post is about beyond just the title.

UK is also main contact for the following countries: Ireland.

Swedish Orphan Biovitrum engages in the development, marketing, and distribution of orphan products and specialty pharmaceuticals. It offers drugs for the 11 hours ago Swedish Orphan Biovitrum (Sobi) is a Swedish biopharmaceutical company that is focused on treating rare diseases. The company operates Sep 29, 2020 Sweden's Sobi eyes Russian expansion Swedish Orphan Biovitrum (STO: SOBI), the Nordic biotech company known as Sobi, and specializes Årsstämma i Swedish Orphan Biovitrum AB (Sobi™), kommer att äga rum Sobis Års- och hållbarhetsredovisning för 2020 finns nu tillgänglig.